On September 10, 2020, the Top 50 Chinese Biopharmaceutical Researchers 2020 was released at the 2020 Conference on the High-quality Development of the Health Care Industry & The 4^th China Pharmaceutical R&D Innovation Summit (PDI). Fosun Pharma ranked first with its R&D investment and remarkable achievements in innovative small-molecule drugs, innovative monoclonal antibody biological drugs and biological analog drugs, and CAR-T cell drugs.

From 2016 to 2019, China's biopharmaceutical market size increased from USD 329.928 billion to USD 371.386 billion with an average annual compound growth rate of 4.02%, ranking first in the pharmaceutical industry. It is expected that the market scale will exceed USD 400 billion during the 2020–2021 year.

Meanwhile, in the biopharmaceutical market, original biomedicines have enjoyed first-mover and patent advantages and taken an absolute leading position in revenue share over the years, and the "monoclonal antibody products" have topped the sub-categories in recent years. With the expiration of several vital monoclonal antibody drug patents, biological analog drugs are gradually stepping into a fast development period with over 40% global growth rate while the market scale has also grown significantly.

As a leading medical and health care group in China, Fosun Pharma, to an extent, is a leading force of China's biological agent industry. Since 2017, Fosun Pharma's comprehensive R&D strength has been ranking in the top five nationwide. In 2019, Fosun Pharma's R&D cost reached RMB 2.041 billion, with a year-over-year increase of 37.97%, and its R&D investment in pharmaceutical business amounted to RMB 3.131 billion, with a year-over-year growth of 39.12%, accounting for 14.38% of its pharmaceutical business revenue.

Thanks to the significant investment, Fosun Pharma has delivered innovative solutions and achieved transformational success. By the end of 2019, Fosun Pharma had 264 ongoing research projects, including new drugs, generic drugs, biological analog drugs, and generic drug consistency evaluation, among which there were 19 innovative small-molecule drug projects, 12 innovative biological drug projects, 21 biological analog drug projects, 133 international standard generic drug projects, 49 generic drug consistency evaluation projects, 2 traditional Chinese medicine projects, and 28 imported drug projects, including 8 imported innovative drug projects and 20 imported generic drug projects.

Furthermore, in 2019, Rituximab Injection (Henlius) became the first biological analog drug approved for the Chinese market. It was marketed in mid-May 2019 and quickly rose in the market. The annual sales revenue in 2019 reached around RMB 150 million, the accumulative revenue in the first half of 2020 was RMB 224 million, and the sales revenue in June topped RMB 100 million. Furthermore, the marketing application of the monoclonal antibody biological analog drugs (trastuzumab for injection and adalimumab injection) was accepted by China's regulatory authority and was brought into the priority review process.

Various sources of information fully display the extensive business layout of Fosun Pharma in the sector of biological medicine, and it proves Fosun Pharma's strong commitment to innovation and internationalization. In the first half of 2020, Fosun Pharma, guided by innovation and internationalization and driven by innovation and R&D, further strengthened its R&D investments. In the first half of the year, Fosun Pharma invested RMB 1.689 billion in R&D with a year-over-year increase of 25.02%, and the RMB 1.204 billion R&D cost grew by 41.81% compared with the same period in 2019. As of June 30, 2020, Fosun Pharma had 248 ongoing research projects, including new drugs, generic drugs, biological analog drugs, and generic drug consistency evaluation.

Fosun Pharma's forward-looking strategy will adhere to the development mode of "innovative transformation, integrated operation, and steady growth", actively make innovation-oriented efforts, and strive to achieve innovative transformation in the short and medium term. Meanwhile, Fosun Pharma will also maintain robust global development and enhance international competitiveness in fulfilling operational requirements and implementing market expansion strategies.